Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 851 - 900 of 1868 results
- Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
- Novel Exosome-Targeted CD4+ T Cell Vaccine Counteracting CD4+25+ Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory CD8+ CTL Responses.
- IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells.
- Immunotherapy with Antibody-Targeted HLA Class I Complexes: Results of in vivo Tumour Cell Killing and Therapeutic Vaccination.
- CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.
- Potent induction of TNF-alpha during interaction of immune effectors with oral tumors as a potential mechanism for the loss of NK cell viability and function.
- Purification and characterization of RGD tumor-homing peptide conjugated human tumor necrosis factor alpha over-expressed in Escherichia coli.
- Dendritic Cells Reconstituted with a Human Heparanase Gene Induce Potent Cytotoxic T-Cell Responses against Gastric Tumor Cells in vitro.
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
- Bipiperidinyl Carboxylic Acid Amides as Potent, Selective, and Functionally Active CCR4 Antagonists.
- Cooperation of the pro-apoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin's lymphoma xenografts.
- Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with Interferon alpha and Verapamil.
- Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
- Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8(+)CD62L (hi) cells and results in superior anti-tumor activity in a tolerogenic murine model.
- Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.
- A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
- Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer.
- Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
- Type 1 CD8+ T Cells are Superior to Type 2 CD8+ T Cells in Tumor Immunotherapy due to Their Efficient Cytotoxicity, Prolonged Survival and Type 1 Immune Modulation.
- Enhancement of Antitumor Effect of Tegafur/Uracil (UFT) plus Leucovorin by Combined Treatment with Protein-Bound Polysaccharide, PSK, in Mouse Models.
- Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
- Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status.
- TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction.
- The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma.
- Improved Mobilization of Peripheral Blood CD34(+) Cells and Dendritic Cells by AMD3100 plus Granulocyte-Colony-Stimulating Factor in Non-Hodgkin's Lymphoma Patients.
- Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy.
- Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
- Targeting Lymphotoxin {beta} Receptor with Tumor-Specific T Lymphocytes for Tumor Regression.
- Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids.
- Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network.
- Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases.
- Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin(R) are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
- An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
- Blockade of Hyaluronan Inhibits IL-2-Induced Vascular Leak Syndrome and Maintains Effectiveness of IL-2 Treatment for Metastatic Melanoma.
- DAP10 Deficiency Breaks the Immune Tolerance against Transplantable Syngeneic Melanoma.
- Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
- Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
- Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
- The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity.
- Development of standardized cell culture conditions for tumor cells with potential clinical application.
- GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
- Evidence of Specificity of Radiolabeled Phage Display Peptides for the TAG-72 Antigen.
- Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab.
- Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus.
- Systemic Delivery of {gamma}134.5-Deleted Herpes Simplex Virus-1 Selectively Targets and Treats Distant Human Xenograft Tumors That Express High MEK Activity.
- Gene-Engineered Varicella-Zoster Virus Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function.
- Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.
- Antitumor Effect of Antibody against a SEREX-Defined Antigen (UOEH-LC-1) on Lung Cancer Xenotransplanted into Severe Combined Immunodeficiency Mice.
- Knockdown of RCAS1 expression by RNA interference recovers T cell growth and proliferation.
- Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393.